Rheumatoid Arthritis

Medications that inhibit interleukin-1beta (IL-1beta), which is a molecule that simulates the immune system, is given to rheumatoid arthritis patients. These patients are more likely to experience invasive Group A Streptococcal infections than patients not on the drug, according to University of California San Diego School of Medicine researchers. It also uncovers a critical new role for IL-1beta as the body’s independent early warning system for bacterial infections. Their study was published in Science Immunology.

Being better equipped to design more personalized and targeted therapies for auto immune diseases occurs, when more is known about each step in the body’s immune …read more